Mitsubishi Tanabe Estimates Sales Decline, Net Profit Increases
This article was originally published in PharmAsia News
Executive SummaryMitsubishi Tanabe Pharma announced estimated sales and income for fiscal year 2009, with sales estimated to decrease by 1.6 percent to ¥408 billion ($4.1 billion) and operational income declining by 11.4 percent to ¥63.5 billion ($646 million). The company estimated a 22.5 percent increase in net profit to ¥32.5 billion ($330 million). The annual dividend is kept the same at ¥28 per share. (Click here for more - Japanese language)
You may also be interested in...
Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.